China’s new cancer drug Toripalimab is approved in the US but will cost 30 times more
China’s new cancer drug Toripalimab is approved in the US but will cost 30 times more
www.scmp.com US$280 in China, US$8,892 in the US: new Chinese cancer drug gets FDA approval
Following the approval of Toripalimab by the Food and Drug Administration, two more Chinese-made cancer drugs have received approval for distribution in the US.
2
comments
Cheap R&D overseas and reap the profits in the US. It’s the new norm for capitalism
Because, of course it does.